GO DEEPER WITH OUR
DOCTORS

Dr. David Leffell is an academic physician, writer, lecturer, and researcher, with over 40 years of experience in his field. Currently, he is Chief of Dermatologic Surgery and Cutaneous Oncology, as well as the David Paige SmithProfessor of Dermatology and Surgery at the Yale School of Medicine. Dr. Leffell’s expertise and vast experience in setting standards for clinical trials was applied to the development of Symphonic M.D. 's rigorous testing protocols.

Dr. David Leffell’s clinical focus is the diagnosis, treatment, and prevention of melanoma and nonmelanoma skin cancer and new diagnostic and therapeutic technologies in skin health. He holds patents for a skin laser method and the skin cancer gene. Throughout his career, he has trained over 100 residents and 30 fellows in dermatologic surgery and skin cancer. 

He graduated from McGill University and Yale University School of Medicine, and for 15 years was CEO of YaleMedicine, one of the country's largest academic group practices, providing speciality care in more than 120 medicalareas. For almost a decade Dr. Leffell was also deputy dean for clinical affairs at Yale University School of Medicine Responsible for relations with Yale New Haven Hospital, strategic development and clinical trials oversight.

Dr. Leffell was raised in Montreal, Canada and received his BS, cum laude from Yale College and his MD, CM fromMcGill University Faculty of Medicine. He completed residencies in internal medicine at Cornell Cooperating Hospitals and in dermatology at Yale-New Haven Hospital. In 1986, he was a post-doctoral National Institutes of Healthresearch fellow. After a fellowship in advanced dermatologic surgery at the University of Michigan he returned toYale in 1988 to found a new clinical and research program in skin cancer and melanoma. 

He currently serves as Chair of the Tullis Health Investors’ Advisory Board along with serving on the board ofXequelBio, Skinosive, DocMatter and BiologicsMD.

The author of more than 200 publications, Dr. Leffell has served as an editor of the world’s leading textbook of dermatology, ‘Fitzpatrick’s Dermatology in General Medicine,’ and has appeared extensively in print and digital media.He is also the author ‘Total Skin: The Definitive Guide to Whole Skin Care for Life,’ which is considered the go-to reference for information about skin health.

Dr. David Chernoff is a molecular diagnostics and biopharmaceutical industry veteran with over 25 years of global experience. He currently serves as the Chief Medical Officer at Intrinsic Capital Partners,overseeing the research and development of Symphonic M.D. formulas. 

As a rheumatologist, Dr. Chernoff has a passion for studying the root causes of inflammation and its manifestations within the body and skin -- the very mission behind developing Symphonic M.D. 

After graduating from Yale University and New York University Grossman School of Medicine, Dr. Chernoffcompleted his residency at UC San Francisco, ultimately serving as Chief Resident (Medicine), Fellow(Rheumatology; Infectious Disease), and Attending Physician (Medical Service), at San Francisco GeneralHospital. Additional credentials include: St. Luke’s Hospital in San Francisco as ER Attending Physician;Associate Director of the AIDS Clinic at UC San Francisco; and, Assistant Chief of Medicine at the UCMedical Center in San Francisco.

Currently, Dr. Chernoff serves as the Chair of Science & Innovation at Schiff Institute, and Chief MedicalOfficer at SetPoint Medical. Dr. Chernoff has served as a translational medical consultant for companies including Adamas, Aquinox, and Crescendo Bioscience. Throughout his career he has played pivotal roles moving early-stage R&D programs successfully through clinical development, product commercialization and evaluating in-license opportunities.

A beauty industry veteran, Cherry Robinson is the Founder & General Manager of Symphonic M.D., a revolutionary new skincare brand from a progressive collective of leading academics, doctors, researchers, inventors, and developers with the forward-thinking mission to unleash the potential of science to challenge skincare conventions and safely solve more skincare concerns for more people.

Robinson’s passion for driving brand innovation and value, coupled with her 33 years of experience in strategic marketing, product development, and global distribution, primed her for her role as Partner at Intrinsic Capital Partners, the parent company of Symphonic M.D. Working in tandem with advisory board doctors, Dr. David Leffell and Dr. David Chernoff, Robinson was able to synthesize and apply their scientific hypothesis regarding the use of bio-functionals and cannabidiols to treat the root causes of inflammation as they relate to the most common skin concerns. The result was formulation of the proprietary bio-functional complex, BioA³ – a potent anti-inflammatory, anti-microbial, and anti-oxidant agent that ensures the stability, enhancement, and efficacy of active compounds while serving as a shield to protect against adverse reactions.

Prior to her current role, Robinson was CEO of DCL Skincare, and EVP/GM USA at Maison Berger Paris. 

Throughout her career, Robinson has worked across key beauty and wellness categories including skincare, color cosmetics, haircare, fragrance and OTCs. She began her career in prestige fragrance marketing at Unilever, before relocating to Panama for a key education role with Chanel color cosmetics. Following that, Robinson was the Global Director of Product Development and Innovation, and then Managing Director at Schwarzkopf Limited, working across both fragrance and haircare. She also held the position of Global CMO of Consumer Products and Pharmaceuticals at Finlayson Enterprises.

Robinson is a graduate of the University of New Brunswick in Canada.